Literature DB >> 15654019

Distinct subcellular location of the Ca2+-binding protein S100A1 differentially modulates Ca2+-cycling in ventricular rat cardiomyocytes.

Patrick Most1, Melanie Boerries, Carmen Eicher, Christopher Schweda, Mirko Völkers, Thilo Wedel, Stefan Söllner, Hugo A Katus, Andrew Remppis, Ueli Aebi, Walter J Koch, Cora-Ann Schoenenberger.   

Abstract

Calcium is a key regulator of cardiac function and is modulated through the Ca2+-sensor protein S100A1. S100 proteins are considered to exert both intracellular and extracellular functions on their target cells. Here we report the impact of an increased intracellular S100A1 protein level on Ca2+-homeostasis in neonatal ventricular cardiomyocytes in vitro. Specifically, we compare the effects of exogenously added recombinant S100A1 to those resulting from the overexpression of a transduced S100A1 gene. Extracellularly added S100A1 enhanced the Ca2+-transient amplitude in neonatal ventricular cardiomyocytes (NVCMs) through a marked decrease in intracellular diastolic Ca2+-concentrations ([Ca2+]i). The decrease in [Ca2+]i was independent of sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) activity and was probably the result of an increased sarcolemmal Ca2+-extrusion through the sodium-calcium exchanger (NCX). At the same time the Ca2+-content of the sarcoplasmic reticulum (SR) decreased. These effects were dependent on the uptake of extracellularly added S100A1 protein and its subsequent routing to the endosomal compartment. Phospholipase C and protein kinase C, which are tightly associated with this subcellular compartment, were found to be activated by endocytosed S100A1. By contrast, adenoviral-mediated intracellular S100A1 overexpression enhanced the Ca2+-transient amplitude in NVCMs mainly through an increase in systolic [Ca2+]i. The increased Ca2+-load in the SR was based on an enhanced SERCA2a activity while NCX function was unaltered. Overexpressed S100A1 colocalized with SERCA2a and other Ca2+-regulatory proteins at the SR, whereas recombinant S100A1 protein that had been endocytosed did not colocalize with SR proteins. This study provides the first evidence that intracellular S100A1, depending on its subcellular location, modulates cardiac Ca2+-turnover via different Ca2+-regulatory proteins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15654019     DOI: 10.1242/jcs.01614

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  22 in total

Review 1.  The cardiokine story unfolds: ischemic stress-induced protein secretion in the heart.

Authors:  Shirin Doroudgar; Christopher C Glembotski
Journal:  Trends Mol Med       Date:  2011-02-01       Impact factor: 11.951

2.  S100A1 DNA-based Inotropic Therapy Protects Against Proarrhythmogenic Ryanodine Receptor 2 Dysfunction.

Authors:  Julia Ritterhoff; Mirko Völkers; Andreas Seitz; Kristin Spaich; Erhe Gao; Karsten Peppel; Sven T Pleger; Wolfram H Zimmermann; Oliver Friedrich; Rainer H A Fink; Walter J Koch; Hugo A Katus; Patrick Most
Journal:  Mol Ther       Date:  2015-05-25       Impact factor: 11.454

Review 3.  Gene therapy targets in heart failure: the path to translation.

Authors:  P W J Raake; H Tscheschner; J Reinkober; J Ritterhoff; H A Katus; W J Koch; P Most
Journal:  Clin Pharmacol Ther       Date:  2011-08-24       Impact factor: 6.875

4.  BMP-2 and FGF-2 synergistically facilitate adoption of a cardiac phenotype in somatic bone marrow c-kit+/Sca-1+ stem cells.

Authors:  Brent R Degeorge; Marc Rosenberg; Volker Eckstein; Erhe Gao; Nicole Herzog; Hugo A Katus; Walter J Koch; Norbert Frey; Patrick Most
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

5.  Differential effects of S100 proteins A2 and A6 on cardiac Ca(2+) cycling and contractile performance.

Authors:  Wang Wang; Michelle L Asp; Guadalupe Guerrero-Serna; Joseph M Metzger
Journal:  J Mol Cell Cardiol       Date:  2014-03-11       Impact factor: 5.000

Review 6.  S100A1: a regulator of striated muscle sarcoplasmic reticulum Ca2+ handling, sarcomeric, and mitochondrial function.

Authors:  Mirko Völkers; David Rohde; Chelain Goodman; Patrick Most
Journal:  J Biomed Biotechnol       Date:  2010-03-28

Review 7.  S100A1: a multifaceted therapeutic target in cardiovascular disease.

Authors:  David Rohde; Julia Ritterhoff; Mirko Voelkers; Hugo A Katus; Thomas G Parker; Patrick Most
Journal:  J Cardiovasc Transl Res       Date:  2010-07-20       Impact factor: 4.132

8.  Bioactive nanoparticles improve calcium handling in failing cardiac myocytes.

Authors:  Joshua T Maxwell; Inthirai Somasuntharam; Warren D Gray; Ming Shen; Jason M Singer; Bo Wang; Talib Saafir; Brian H Crawford; Rong Jiang; Niren Murthy; Michael E Davis; Mary B Wagner
Journal:  Nanomedicine (Lond)       Date:  2015-07-30       Impact factor: 5.307

Review 9.  S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy.

Authors:  Carolin Kraus; David Rohde; Christian Weidenhammer; Gang Qiu; Sven T Pleger; Mirko Voelkers; Melanie Boerries; Andrew Remppis; Hugo A Katus; Patrick Most
Journal:  J Mol Cell Cardiol       Date:  2009-06-16       Impact factor: 5.000

10.  Post-translational S-nitrosylation is an endogenous factor fine tuning the properties of human S100A1 protein.

Authors:  Martina Lenarčič Živković; Monika Zaręba-Kozioł; Liliya Zhukova; Jarosław Poznański; Igor Zhukov; Aleksandra Wysłouch-Cieszyńska
Journal:  J Biol Chem       Date:  2012-09-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.